Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
Top Cited Papers
Open Access
- 1 January 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Ionizing radiation (IR) is a non-specific but highly effective way to kill malignant cells. However, tumor recurrence sustained by a minor fraction of surviving tumor cells is a commonplace phenomenon caused by the activation of both cancer cell intrinsic resistance mechanisms, and also extrinsic intermediaries of therapy resistance, represented by non-malignant cells and structural components of the tumor stroma. The improved accuracy offered by advanced radiotherapy (RT)-technology permits reduced volume of healthy tissue in the irradiated field, and has been triggering an increase in the prescription of high-dose oligo-fractionated regimens in the clinics. Given the remarkable clinical success of high-dose RT and the current therapeutic shift occurring in the field, in this review we revise the existing knowledge on the effects that different radiation regimens exert on the different compartments of the tumor microenvironment, and highlight the importance of anti-tumor immunity and other tumor cell extrinsic mechanisms influencing therapeutic responses to high-dose radiation.This publication has 100 references indexed in Scilit:
- Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell RadiosensitizerInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent MannerCancer Cell, 2010
- Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretionNature, 2009
- The Linear-Quadratic Model Is an Appropriate Methodology for Determining Isoeffective Doses at Large Doses Per FractionSeminars in Radiation Oncology, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic CellsCancer Cell, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesNature Medicine, 2006
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Stromal fibroblasts in cancer initiation and progressionNature, 2004